Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
Crossref DOI link: https://doi.org/10.1007/s00280-016-3106-7
Published Online: 2016-07-15
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yonemori, Kan
Tamura, Kenji
Kodaira, Makoto
Fujikawa, Koshi
Sagawa, Tamotsu
Esaki, Taito
Shirakawa, Tsuyoshi
Hirai, Fumihiko
Yokoi, Yuki
Kawata, Toshio
Hatano, Ben
Takahashi, Yasuo
Funding for this research was provided by:
AstraZeneca
License valid from 2016-07-15